<DOC>
	<DOCNO>NCT00782184</DOCNO>
	<brief_summary>Participants currently take atorvastatin 20 mg switch either atorvastatin 40 mg ezetimibe/simvastatin 10 mg/40 mg ( 10/40 ) . After 6 week treatment , percent reduction low-density lipoprotein cholesterol ( LDL-C ) assess compare two treatment group .</brief_summary>
	<brief_title>Ezetimibe/Simvastatin ( 10 mg/40 mg ) vs. Doubling Atorvastatin High Risk Participants ( MK-0653A-134 AM1 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Ezetimibe , Simvastatin Drug Combination</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>Participants either statin naive approve lipid lower therapy 6 week prior study initiation Participant meet Adult Treatment Panel ( ATP ) III High Risk criterion Females pregnant breastfeed Participant consume 14 alcoholic beverage per week Participant treat investigational drug within last 30 day Participant congestive heart failure ( New York Heart Association [ NYHA ] Type III IV ) Participant gastric bypass Participant newly diagnose type 1 2 diabetes Participant Human Immunodeficiency Virus ( HIV ) positive Participant history drug alcohol abuse within last 5 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>